Loading
Life sciences · Observational Study
ClinicalTrials.gov · October 7, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Observational Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07345169). This is a study registration, not published results. Lead sponsor: Assistance Publique - Hôpitaux de Paris. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 540 participants (ESTIMATED). Conditions: Critical Illness, Intensive Care Patients, Critical Illness Requiring Intensive Care - Sepsis, Critical Illness Requiring Intensive Care - Acute Brain Injury, Critical Illness Requiring Intensive Care - Major Surgery, Critical Illness Requiring Intensive Care - Polytrauma. Primary outcome measures: Overall survival of patients admitted to intensive care. , 12 months; Multidimensional flow cytometry leukocyte profiling , Change from baseline to 12 months; Inflammatory profile of ICU patients , Change from baseline to 12 months. Brief summary: This is a prospective observational physiopathological study aimed at evaluating the immunological and inflammatory determinants associated with the prognosis of patients admitted to intensive care units (ICU). The study will establish multidimensional models predicting one-year survival and the occurrence of nosocomial infections. Patients admitted to ICU undergo routine biological sampling. In addition to these, minimal supplementary samples will be collected for immunological and inflammatory biomarker analysis at admission, day 1, day 4, day 8, ICU discharge or day 28, and at 12 months. Additional samples may be taken during clinically significant events (nosocomial infections, complications).